Literature DB >> 20842600

Triptans: where things stand.

Alan K Cole1, Michael J Marmura.   

Abstract

OPINION STATEMENT: Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication.

Entities:  

Year:  2010        PMID： 20842600     DOI： 10.1007/s11940-010-0082-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN： 1092-8480            Impact factor:   3.598


  56 in total

1.  The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.

Authors:  M J Cumberbatch; R G Hill; R J Hargreaves
Journal:  Eur J Pharmacol       Date:  1998-11-27       Impact factor: 4.432

Review 2.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.

Authors:  W H Visser; N M Jaspers; R H de Vriend; M D Ferrari
Journal:  Cephalalgia       Date:  1996-12       Impact factor: 6.292

4.  Treatment of hemiplegic migraine with triptans.

Authors:  V Artto; M Nissilä; M Wessman; A Palotie; M Färkkilä; M Kallela
Journal:  Eur J Neurol       Date:  2007-09       Impact factor: 6.089

5.  Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.

Authors:  Stewart Tepper; Christopher Allen; David Sanders; Alison Greene; Stephen Boccuzzi
Journal:  Headache       Date:  2003-01       Impact factor: 5.887

Review 6.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Authors:  David Dodick; Richard B Lipton; Vincent Martin; Vasilios Papademetriou; Wayne Rosamond; Antoinette MaassenVanDenBrink; Hassan Loutfi; K Michael Welch; Peter J Goadsby; Steven Hahn; Susan Hutchinson; David Matchar; Stephen Silberstein; Timothy R Smith; R Allan Purdy; Jane Saiers
Journal:  Headache       Date:  2004-05       Impact factor: 5.887

7.  The discovery and development of the triptans, a major therapeutic breakthrough.

Authors:  Patrick P A Humphrey
Journal:  Headache       Date:  2008-05       Impact factor: 5.887

8.  Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.

Authors:  S D Silberstein; L K Mannix; J Goldstein; J R Couch; S C Byrd; M H Ames; S A McDonald; S E Lener; Cynthia Toso
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

9.  Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

Review 10.  Early treatment in migraine: how strong is the current evidence?

Authors:  A Gendolla
Journal:  Cephalalgia       Date:  2008-09       Impact factor: 6.292
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.